Patents by Inventor Jennifer Riggs-Sauthier

Jennifer Riggs-Sauthier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Multi-arm polymeric alkanoate conjugates
    Patent number: 11672776
    Abstract: Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: June 13, 2023
    Assignee: Nektar Therapeutics
    Inventors: Antoni Kozlowski, Samuel P. McManus, Jennifer Riggs-Sauthier, Xiaoming Shen, Wen Zhang
  • Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
    Patent number: 11612662
    Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: March 28, 2023
    Assignee: Nektar Therapeutics
    Inventors: Lin Cheng, Jennifer Riggs-Sauthier
  • Oligomer-corticosteroid conjugates
    Patent number: 11464788
    Abstract: The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: October 11, 2022
    Assignee: Nektar Therapeutics
    Inventors: Wen Zhang, Jennifer Riggs-Sauthier, J. Milton Harris, Michael D. Bentley
  • OLIGOMER-CORTICOSTEROID CONJUGATES
    Publication number: 20220072010
    Abstract: The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 10, 2022
    Inventors: Wen Zhang, Jennifer Riggs-Sauthier, J. Milton Harris, Michael D. Bentley
  • Polymer-semaxanib moiety conjugates
    Patent number: 11007270
    Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: May 18, 2021
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
  • Oligomer-beta blocker conjugates
    Patent number: 10881738
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: January 5, 2021
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
  • Oligomer-phenothiazine conjugates
    Patent number: 10869933
    Abstract: The invention relates to (among other things) oligomer-phenothiazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated phenothiazine compounds.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: December 22, 2020
    Assignee: Nektar Therapeutics
    Inventors: Xuyuan Gu, Jennifer Riggs-Sauthier
  • Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
    Patent number: 10844076
    Abstract: The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: November 24, 2020
    Assignee: Nektar therapeutics
    Inventors: Pankaj Sharma, Vijay Kumar Khatri, Xuyuan Gu, Yuan Song, Michael Lixin Shen, Jennifer Riggs-Sauthier, Neel K. Anand, Antoni Kozlowski, Aleksandrs Odinecs, Timothy A. Riley, Zhongxu Ren, YongQi Mu, Xiaoming Shen, Xuejun Yuan, Natalia Aurrecoechea, Donogh John Roger O'Mahony, Bo-Liang Deng
  • MULTI-ARM POLYMERIC PRODRUG CONJUGATES OF PEMETREXED-BASED COMPOUNDS
    Publication number: 20200323992
    Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Inventors: Lin Cheng, Jennifer Riggs-Sauthier
  • Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
    Patent number: 10736969
    Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: August 11, 2020
    Assignee: Nektar Therapeutics
    Inventors: Lin Cheng, Jennifer Riggs-Sauthier
  • OLIGOMER-OPIOID AGONIST CONJUGATES
    Publication number: 20200078353
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Application
    Filed: November 13, 2019
    Publication date: March 12, 2020
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • OLIGOMER-PHENOTHIAZINE CONJUGATES
    Publication number: 20200038517
    Abstract: The invention relates to (among other things) oligomer-phenothiazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated phenothiazine compounds.
    Type: Application
    Filed: October 11, 2019
    Publication date: February 6, 2020
    Inventors: Xuyuan Gu, Jennifer Riggs-Sauthier
  • POLYMER-SEMAXANIB MOIETY CONJUGATES
    Publication number: 20200030451
    Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
    Type: Application
    Filed: October 3, 2019
    Publication date: January 30, 2020
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
  • Oligomer-opioid agonist conjugates
    Patent number: 10512644
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: December 24, 2019
    Assignee: Inheris Pharmaceuticals, Inc.
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Oligomer-phenothiazine conjugates
    Patent number: 10485877
    Abstract: The invention relates to (among other things) oligomer-phenothiazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated phenothiazine compounds.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: November 26, 2019
    Assignee: Nektar Therapeutics
    Inventors: Xuyuan Gu, Jennifer Riggs-Sauthier
  • Polymer-semaxanib moiety conjugates
    Patent number: 10463744
    Abstract: The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: November 5, 2019
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald, Sean M. Culbertson
  • Oligomer-containing benzamide-based compounds
    Patent number: 10434181
    Abstract: The invention relates to (among other things) oligomer-containing benzamide-based compound compounds. A compound of the invention exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: October 8, 2019
    Assignee: Nektar Therapeutics
    Inventors: Lin Cheng, Jennifer Riggs-Sauthier, Neel K. Anand
  • OLIGOMER-OPIOID AGONIST CONJUGATES
    Publication number: 20190247388
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 15, 2019
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • OLIGOMER-BETA BLOCKER CONJUGATES
    Publication number: 20190175743
    Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits a different biological membrane crossing rate as compared to the biological membrane crossing rate of the small molecule drug not attached to the water-soluble oligomer.
    Type: Application
    Filed: February 15, 2019
    Publication date: June 13, 2019
    Inventors: Jennifer Riggs-Sauthier, Franco J. Duarte, Aaron S. Hammons
  • Oligomer-opioid agonist conjugates
    Patent number: 10307416
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: June 4, 2019
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley